Amgen Inc. (AMGN)
Amgen's gastric cancer drug meets late-stage trial goal
Amgen said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
Here's Why Amgen (AMGN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Amgen (AMGN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
What's Happening With Amgen Stock?
Amgen stock (NASDAQ:AMGN) fell 6% on Monday, June 23, 2025, after mid-stage clinical trial results for its long-acting experimental obesity drug, MariTide, revealed a need for a low starting dose to mitigate side effects like vomiting. Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase with an eight-week dose escalation period.
Amgen Inc. (AMGN) Presents at Special Call (IR Call) Conference Transcript
Amgen Inc. (NASDAQ:AMGN ) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Company Participants Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & Development Susan Sweeney - Executive Vice President of Obesity & Related Conditions Murdo Gordon - Executive Vice President of Global Commercial Operations Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Michael Yee - Jefferies LLC, Research Division Yaron Werber - TD Cowen, Research Division Terence Flynn - Morgan Stanley, Research Division Trung Huynh - UBS Investment Bank, Research Division Evan Seigerman - BMO Capital Markets Equity Research David Amsellem - Piper Sandler & Co., Research Division David Risinger - Leerink Partners LLC, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Taylor Hanley - JPMorgan Chase & Co, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Courtney Breen - Sanford C.
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Amgen (AMGN) closed at $272.44, marking a -5.84% move from the previous day.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen: Imdelltra Data And Q1 Results Impress
Despite the weak performance of Amgen's rare disease portfolio, it once again beat consensus non-GAAP EPS and revenue estimates. So, the main contributors to strengthening Amgen's balance sheet and improving its margins in the first quarter of 2025 were Blincyto, Tezspire, Prolia, and Imdelltra. In its oncology franchise, I highlight Imdelltra as the 'crown jewel,' with sales of $81 million in the first three months of 2025, up 20.9% quarter-on-quarter.
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
Amgen (AMGN) closed at $297.29 in the latest trading session, marking a +1.88% move from the prior day.
Here's Why Amgen (AMGN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amgen Inc. (AMGN) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Amgen Inc. (NASDAQ:AMGN ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 9:20 PM ET Company Participants James E. Bradner - Executive Vice President of Research & Development Justin G.
